clinical trial · NCT06173531
Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome
Hyperphagia in Prader-Willi SyndromeCarbetocinPlacebo
brief summary
12-week, randomized, double-blind, placebo-controlled, parallel-group study of carbetocin nasal spray for the treatment of hyperphagia in Prader-Willi syndrome (PWS)
started
Nov 27, 2023
primary completion
Oct 1, 2025
completion
Nov 1, 2025
last updated
Sep 10, 2025
detailed description
This is a 12-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study comparing carbetocin nasal spray 3.2 mg TID with placebo (matched placebo nasal spray TID) in subjects with PWS.
official title
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol